Charles Schwab Investment Management Inc. Acquires 104,085 Shares of Evolent Health, Inc $EVH

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Evolent Health, owning approximately 1,023,077 shares valued at $9.69 million, reflecting an 11.3% boost in the first quarter.
• Evolent Health reported an earnings per share (EPS) of ($0.10) for the last quarter, missing estimates and experiencing a 31.3% decline in revenue year-over-year.
• Analysts have set a consensus target price of $17.93 for Evolent Health, with most ratings being positive, including twelve "Buy" ratings.

Charles Schwab Investment Management Inc. grew its holdings in shares of Evolent Health, Inc (NYSE:EVH - Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,023,077 shares of the technology company's stock after acquiring an additional 104,085 shares during the period. Charles Schwab Investment Management Inc. owned about 0.88% of Evolent Health worth $9,689,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of EVH. Raymond James Financial Inc. bought a new position in shares of Evolent Health during the fourth quarter worth about $2,542,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Evolent Health by 18.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 36,498 shares of the technology company's stock valued at $346,000 after buying an additional 5,712 shares during the last quarter. Brighton Jones LLC bought a new stake in shares of Evolent Health during the fourth quarter valued at approximately $3,927,000. Brevan Howard Capital Management LP bought a new stake in shares of Evolent Health during the fourth quarter valued at approximately $613,000. Finally, One68 Global Capital LLC acquired a new position in shares of Evolent Health during the fourth quarter valued at approximately $4,061,000.

Evolent Health Price Performance

Shares of EVH stock traded down $0.01 during trading hours on Friday, reaching $9.63. 1,367,209 shares of the company were exchanged, compared to its average volume of 3,798,335. The stock's fifty day moving average is $10.16 and its two-hundred day moving average is $9.55. Evolent Health, Inc has a fifty-two week low of $7.06 and a fifty-two week high of $32.35. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -5.98 and a beta of 0.82. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.01 and a quick ratio of 1.01.

Evolent Health (NYSE:EVH - Get Free Report) last posted its earnings results on Thursday, August 7th. The technology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.20). Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The firm had revenue of $444.33 million during the quarter, compared to analyst estimates of $459.43 million. During the same quarter last year, the business posted $0.30 earnings per share. The company's revenue for the quarter was down 31.3% on a year-over-year basis. Evolent Health has set its Q3 2025 guidance at EPS. Sell-side analysts forecast that Evolent Health, Inc will post 0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

EVH has been the topic of several recent research reports. Needham & Company LLC restated a "buy" rating and issued a $15.00 price target on shares of Evolent Health in a research report on Tuesday, May 13th. Truist Financial boosted their price target on shares of Evolent Health from $14.00 to $16.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Piper Sandler boosted their price target on shares of Evolent Health from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Thursday. UBS Group boosted their price target on shares of Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a report on Friday, May 9th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $13.00 price objective on shares of Evolent Health in a research note on Friday, June 20th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Evolent Health has a consensus rating of "Buy" and a consensus price target of $18.07.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.